Coller Capital
Allocate 2018: ESG gains traction with European LPs
Numerous reports and studies have shown that LPs are increasingly concerned about their GPs' environmental, social and governance policies
LP competition heats up for stakes in GP management companies
One in six LPs is taking stakes in GP management companies via specialist funds
Coller leads €2.5bn secondaries deal for Nordic Capital VII
Restructuring of Nordic Capital's seventh fund is one of the largest GP-led secondary transactions inked in Europe
Coller targets $9bn for eighth secondaries fund
Significant increase on Coller VII, which held a final close on $7.15bn in January 2016
Nordic to restructure fund VII, roll €2.2bn into new vehicle
Buyers Goldman Sachs and Coller Capital are offering an 11% premium to NAV to existing LPs
Coller reshuffles management in wake of Burdel departure
Firm promotes Schad and Aguerre in its London team
Prime-time for secondaries
The secondaries segment has clearly been popular with LPs, but can it cope with mounting levels of dry powder?
Ex-Doughty chief Marquardt joins Coller
Former Doughty Hanson CEO announced his plans to leave the GP in December last year
Coller Capital loses senior partner Johansen
Fundraising partner Johansen leaves one week after CEO Tim Jones unexpectedly stepped down from his role
Coller collects $7.15bn for seventh fund
CIP VII was oversubscribed and raised in around six months
National pension funds to boost Italian PE, says Coller's Orsi
Coller's Orsi believes new rules allowing Italian pension funds to invest in PE will have a great impact
Coller’s Tim Jones predicts choppy waters ahead
Tim Jones of Coller Capital discusses the increasingly competitive secondaries market and his outlook for 2015
MPVenture spins out of Monte dei Paschi
Spinout comes as Monte dei Paschi continues cost-cutting programme
Secondaries: A balancing act
Transfers are becoming more complex as cash continues to flood secondaries market
No debt bubble in Europe, LPs say in survey
Investors much more cautious about situation in US
Deal in focus: uniQure raises $91.8m in IPO
Netherlands-based uniQure’s debut on the Nasdaq marks one of the latest in a string of European venture capital-backed biotechs flocking to the US markets, but the lack of activity in Europe's public markets does not necessarily equate to a slowdown...
VC-backed uniQure raises $91.8m in IPO
Venture capital-backed Dutch gene therapy company uniQure raised well above its original expectation in its listing on the Nasdaq, bagging $91.8m.
VC-backed uniQure files $75m IPO
Dutch gene therapy company uniQure, backed by several venture capital firms, plans on raising up to $75m in its IPO on the Nasdaq.
LPs expect net returns of at least 11%
The majority of LPs anticipate annual net returns in excess of 11% over the next three to five years, according to the latest Coller Capital Global Barometer.
Credit Suisse to sell DLJ Merchant Banking to Coller
Credit Suisse Group is to sell its shares in mid-market buyout arm DLJ Merchant Banking Partners to Coller Capital, according to reports.
VC-backed uniQure to float
Dutch gene therapy company uniQure, backed by several venture capital firms, has filed a confidential F-1 form with the US Securities and Exchange Commission (SEC) for a potential IPO.
DFJ Esprit et al. back ZBD
UK-based electronic shelf labelling (ESL) developer ZBD Solutions has secured $25m in fresh capital from a consortium of existing investors and US listed firm Zebra Technologies Corporation.
Omnes finalises spinout, secures €70m commitment for new fund
Omnes Capital, the former private equity arm of French bank Crédit Agricole, has started raising its fourth SME-focused fund and is now wholly owned by its management team.
A vintage year for the secondaries market
Secondaries